Combination of biotransformation by P450 BM3 mutants with on-line post-column bioaffinity and mass spectrometric profiling as a novel strategy to diversify and characterize p38 alpha kinase inhibitors.

Combination of biotransformation by P450 BM3 mutants with on-line post-column bioaffinity and mass spectrometric profiling as a novel strategy to diversify and characterize p38 alpha kinase inhibitors. Rea, V.; Falck, D., Kool, J., de Kanter, F.J. J., Commandeur, J.N.M., Vermeulen, N. P. E., Niessen, W.M.A., Honing, M. Med Chem Comm.Vol: 4, Issue: 2: 371-377. Feb 2013